NCT07705334

Studies / Phase Ia/Ib

Luca-1: SHY-ONC6 (19S proteasome ATPase inhibitor) in advanced solid tumours

SHY Therapeutics · Advanced solid tumours (10 types) incl. soft tissue sarcoma

recruiting

Sites

0

Patients

4

Target N

30

Enrolled

3

Steps done

0/13

Decisions

6

Design

Title
Luca-1: SHY-ONC6 (19S proteasome ATPase inhibitor) in advanced solid tumours
Design
Phase 1a single-patient titration then BOIN escalation; Phase 1b disease-specific expansion
Therapy
SHY-ONC6, oral non-covalent 19S proteasome AAA+ ATPase inhibitor
Primary endpoint
DLTs, AEs and SAEs (CTCAE v6.0); MTD; RP2D

Lifecycle

0 of 13 done

Feasibility assessed

Can this study realistically enroll — sites, patients, timeline?

not started

Protocol drafted & medically reviewed

A protocol synopsis exists, has been linted against SPIRIT, and is through medical review.

not started

Sites activation-ready

Every site's contract, activation and first-patient timeline is within benchmark.

not started

Recruitment funnel and screening plan

Enrollment funnel, accrual pace and eligibility yield computed; candidates to screen proposed per site (import is human-gated).

not started

Sites risk-scored

Per-site KRIs z-scored across the study; statistical outliers get a proposed on-site visit.

not started

Data cleaned

18 edit checks swept AE, DM, SV, EX and LB; deterministic queries auto-closed.

not started

Safety reports triaged

Every reported adverse event triaged with an E2A clock; serious ones with a physician.

not started

Dropout risk scored

Active patients scored; at-risk cohort proposed for outreach.

not started

Termination risk watched

Accrual curve, literature risk profile and registry comparators surveilled; termination itself stays a human decision.

not started

Drug supply forecast

Kits required over the horizon from observed dosing, accrual and discontinuation (partner IRT).

not started

TLFs generated & validated

ICH E3 Section 14 tables from live data (disposition, demographics, exposure, AEs, Kaplan-Meier efficacy), pending double-programming validation.

not started

CSR drafted & signed off

ICH E3 clinical study report assembled from study data; medical sign-off required.

not started

TMF inspection-ready

Trial master file audited against the DIA TMF Reference Model; gaps filed as QA findings.

not started

Sites

0

No sites contracted for this study yet.

Patients

4

Pending decisions

6

assess serious event

Non-serious event needing physician assessment — Grade 1 adverse event, not serious, causality not assessed — investigator assessment required, expectedness undetermined — event not yet coded — under safety physician review (triage only; causality and closure are the physician's)

medium

assess serious event

SAE — SAE Narrative Subject NCT07705334-P02 is a 57-year-old female enrolled in study NCT07705334, treatment arm: [PENDING — human input]. The subject experienced a serious adverse event (Grade 3), currently uncoded, as reported via participant-reported source: Luna chat message, "I've had a high fever since last night." This was a solicited symptom report and requires clinical characterization. Onset date: [PENDING — human input] System organ class: [PENDING — human input] Action taken with study treatment: [PENDING — human input] Outcome: [PENDING — human input] Date of resolution (if applicable): [PENDING — human input] Death within 30 days of event: No Causality: Investigator causality assessment has not yet been recorded. [PENDING — human input] Expectedness: Expectedness undetermined — event not yet coded. [PENDING — human input] Regulatory Reporting: This event has been classified as serious. Per ICH E2A requirements, an expedited report is due on 2026-10-23, consistent with the 15-day reporting clock applicable to other serious unexpected events. This narrative will be updated upon receipt of additional clinical information, including invest [narrative drafted by claude-sonnet-5; verify against source fields]

critical

assess serious event

SAE — SAE Narrative Subject NCT07705334-P02 (57-year-old female; treatment arm: [PENDING — human input]) experienced a serious adverse event, Grade 3 in severity. The event has not yet been coded; the uncoded term is based on participant-reported information via Luna chat ("high fever"), a solicited symptom report that requires clinical characterization. Onset date: [PENDING — human input] System organ class: [PENDING — human input] Action taken with study treatment: [PENDING — human input] Outcome: [PENDING — human input] Resolution date: [PENDING — human input] Investigator causality assessment: not assessed — investigator assessment required. Expectedness: expectedness undetermined — event not yet coded. Seriousness: serious. Death within 30 days of event: no. Regulatory reporting: This event falls under the 15-day expedited reporting timeline (other serious, unexpected) per ICH E2A. The expedited report is due on 2026-10-23. Additional clinical details, including a fully characterized diagnosis, SOC/coded term, and investigator causality assessment, are pending and required prior to finalization of this narrative. [narrative drafted by claude-sonnet-5; verify against source fields]

critical

assess serious event

Non-serious event needing physician assessment — Grade 1 adverse event, not serious, causality not assessed — investigator assessment required, expectedness undetermined — event not yet coded — under safety physician review (triage only; causality and closure are the physician's)

medium

luna withdrawal signal

Participant Kenji Mori voiced withdrawal intent to Luna. Site coordinator outreach requested — participation is voluntary; only support, never pressure.

medium

luna low mood followup

Participant Kenji Mori has reported feeling 2/5 then 2/5 in consecutive Luna check-ins. Proactive site outreach proposed.

medium